DelNova, Inc. is a biopharmaceutical company focused on addressing unmet medical needs. DelNova is resolving complications arising from botulinum toxin therapies (eg. Botox®). The first product under development, ReViVox™ is based on a clinically validated drug currently approved for a different medical use and route of administration. The novel formulation will manage undesirable side effects resulting from neurotoxin injections in both medical and cosmetic applications.
This is a quick episode to describe what to expect from the Innovation4Alpha podcast hosted by Tobin Arthur.
Dr. Gupta is very active working with innovative startups across medical device and digital health and serves as a Sr. Clinical Advisor with AngelMD...
One of the most creative, insightful and articulate startup leaders in the industry, Matan Magril is always fascinating to talk with. At 22, he...
